Lexicon Pharmaceuticals LXRX License — Variable consideration, regulatory milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept lxrx:RevenueVariableConsiderationRegulatoryMilestones.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's license — variable consideration, regulatory milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's license — variable consideration, regulatory milestones?
- Lexicon Pharmaceuticals (LXRX) reported license — variable consideration, regulatory milestones of $465M in Q1 2026.
- What does license — variable consideration, regulatory milestones mean?
- This metric measures revenue recognized upon the achievement of specific regulatory events, such as FDA approvals or clinical trial successes, as defined in licensing agreements. It reflects the successful de-risking of drug candidates through the regulatory process. These payments are critical for funding ongoing research and development activities.